QGEN Qiagen: Forward P/E Multiple

Official company branding of qiagen.com (QGEN)

Qiagen N.V. (QGEN) is implementing ESG principles by reducing plastic use and its carbon footprint within molecular diagnostics. This trend in the company's forward P/E ratio on the GURU.Markets chart confirms this, with the metric currently at 19.10. The business relies on stable laboratory demand with a sales peak in December, while R&D centers develop innovative DNA sequencing and purification systems.

Price to Future Earnings Ratio: Qiagen NV (QGEN) for 07/04/2022 - 11/17/2026

Qiagen (QGEN) - metric breakdowns and financial figures

- stock quotes and analyst forecast:
Basic company analysis:Qiagen Group QGEN
Signature product of qiagen.com

The investment attractiveness of Qiagen N.V. (QGEN) is based on stable demand within the molecular diagnostics sector. The forward P/E compares the market value of the business with expected annual earnings, revealing valuation deviations from the fundamental trend. By analyzing the business's forward P/E, an investor can see capitalization efficiency driven by a reliable cash flow from consumables. This metric allows for the timely identification of whether the asset is overbought or undervalued.

Competing companies

Projected Price to Earnings TEM (Tempus AI, Inc)|Market Cap to Projected Earnings Isis Pharmaceuticals|Forward P/E Multiple RGEN (repligen.com)|Market Cap to Future Earnings Ratio RNA (Avidity Biosciences, Inc.)|CRSP - Future Price to Earnings|Future Price to Earnings Multiple WGS (GeneDx)|RARE: Forward P/E Multiple|Beam Therapeutics Corp - Future Price to Earnings Multiple|Projected Price to Earnings SRPT|twistbioscience.com (TWST) - Market Cap to Projected Earnings|Forward P/E Multiple TXG|NTLA (Intellia) - Future Price to Earnings Multiple|Future Price to Earnings Stoke STOK|BioLife (BLFS) - Projected Price to Earnings Ratio|wavelifesciences.com - Forward P/E Multiple|Price to Expected Earnings Ratio MAZE|SION: Forward P/E Multiple|PRME - Market Cap to Projected Earnings|Projected Price to Earnings TSHA|QURE - Forward Price to Earnings Multiple|Forward P/E Multiple MGTX|Market Cap to Projected Earnings regenxbio.com|Forward P/E Multiple SLDB (Solid Biosciences Inc)|OCGN: Price to Future Earnings Ratio|PACB - Future Price to Earnings|Benitec (BNTC) - Projected Price to Earnings|DSGN: Forward P/E Multiple|RCKT: Market Cap to Future Earnings Ratio|FDMT (4D Molecular Therapeutics, Inc.) - Forward P/E Multiple|lexeotx.com (LXEO) - Market Cap to Projected Earnings|Forward P/E Multiple KRRO|Projected Price to Earnings Editas Medicine, Inc. EDIT|Future Price to Earnings silence-therapeutics.com SLN|PRQR: Price to Future Earnings Ratio|CDXS - Future Price to Earnings|Market Cap to Projected Earnings Sangamo Therapeutics, Inc. SGMO|NAUT (nautilus.bio) - Projected Price to Earnings|Projected Price to Earnings Ratio Metagenomi, Inc. (MGX)|Projected Price to Earnings DTIL|Price to Future Earnings Ratio GBIO (generationbio.com)|Future Price to Earnings Boundless Bio, Inc (BOLD)|Forward P/E Multiple Exicure Inc. (XCUR)|Imunon, Inc. - Projected Price to Earnings|PHIO: Price to Future Earnings Ratio|MBIO - Future Price to Earnings|Price to Expected Earnings Ratio RNAZ|Bionano Genomics, Inc. (BNGO) - Future Price to Earnings|Applied DNA Sciences, Inc. (APDN) - Forward P/E Multiple|BLUE (bluebirdbio.com) - Forward P/E Multiple|Price to Future Earnings Ratio IPA (ImmunoPrecise Antibodies)|Forward P/E Multiple OMGA|Projected Price to Earnings Singular Genomics Systems OMIC|Forward P/E Multiple RGLS (regulusrx.com)|Syros Pharmaceuticals Inc. (SYRS) - Projected Price to Earnings Ratio|TBIO: Projected Price to Earnings|Future Price to Earnings Multiple TCON (TRACON)|UBX: Forward P/E Multiple